Morningstar

U.S. FDA Grants Approval for Jivi® Antihemophilic Factor (Recombinant), PEGylated-aucl in Pediatric Patients 7 to Under 12 Years of Age With Hemophilia A (Congenital Factor ...

U.S. FDA Grants Approval for Jivi® Antihemophilic Factor (Recombinant), PEGylated-aucl in Pediatric Patients 7 to Under 12 Years of Age With Hemophilia A (Congenital Factor VIII Deficiency) Not ...
The New England Journal of Medicine

BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A

Factor VIII replacement products have improved the care of patients with hemophilia A, but the short half-life of these products affects the patients’ quality of life. The half-life of recombinant ...
The American Journal of Managed Care

The Benefits of Sustaining High Factor VIII Levels in People With Hemophilia A

Hemophilia A is characterized by FVIII deficiency, leading to joint bleeds and chronic pain despite prophylactic therapy. Treatment options vary in sustaining FVIII levels, with gene therapy and ...
WebMD

Altuviiio for Hemophilia A

People with severe hemophilia A are at risk for prolonged bleeding events that can cause serious complications. To prevent these bleeding events, most people with this condition get injections of a ...
FierceBiotech

Bayer HealthCare and Maxygen Announce Hematology Agreement

Bayer HealthCare is expanding its commitment to hemophilia with the acquisition of Maxygen's (NASDAQ:MAXY) hemophilia program assets, including a next-generation recombinant Factor VIIa protein known ...
Medical News Today

Treatment for Hemophilia / Haemophilia

Up to a few decades ago a considerable proportion of patients with hemophilia died prematurely because of hemophilia. Tragically, many deaths were the result of childhood injury or surgery. Over the ...
Business Wire

Bioverativ Presents Preliminary Phase 1/2a Data on BIVV001, the First Factor VIII Therapy to Break Through the VWF Half-Life Ceiling in Hemophilia A

WALTHAM, Mass.--(BUSINESS WIRE)--Bioverativ Inc., a Sanofi company dedicated to transforming the lives of people with rare blood disorders, today presented initial clinical data for BIVV001 ...
Morningstar

U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease

− Approval Expands Use of VONVENDI to Include Routine Prophylaxis to Reduce the Frequency of Bleeding Episodes in Adults with Type 1 and 2 Von Willebrand Disease (VWD) and On-Demand and Perioperative ...
FiercePharma

Bayer Submits an Application for Market Authorization of Recombinant Factor VIII Product as a Treatment of Hemophilia A in Japan

Berlin, June 30, 2015 – Bayer HealthCare today announced that Bayer Yakuhin, Ltd., Osaka, Japan, has submitted an application for marketing authorization for BAY 81-8973, a recombinant Factor VIII ...
ascopubs.org

Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery ...

Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: an analysis of two ...